Rapport Therapeutics Inc (RAPP)

Currency in USD
15.20
+0.81(+5.63%)
Closed·
After Hours
15.200.00(0.00%)
·
RAPP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 15 days
Fair Value
Day's Range
14.1015.22
52 wk Range
6.4329.74
Key Statistics
Prev. Close
15.2
Open
14.46
Day's Range
14.1-15.22
52 wk Range
6.43-29.74
Volume
199.91K
Average Volume (3m)
174.33K
1-Year Change
-25.74%
Book Value / Share
7.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RAPP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
35.00
Upside
+130.26%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Rapport Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Rapport Therapeutics Inc Company Profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.

Compare RAPP to Peers and Sector

Metrics to compare
RAPP
Peers
Sector
Relationship
P/E Ratio
−7.0x−0.8x−0.5x
PEG Ratio
−0.07−0.020.00
Price/Book
1.9x1.1x2.6x
Price / LTM Sales
-2.2x3.2x
Upside (Analyst Target)
143.2%161.2%42.7%
Fair Value Upside
Unlock20.6%5.8%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 35.00
(+130.26% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.68 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RAPP Income Statement

People Also Watch

44.47
EXEL
+0.47%
129.77
CRWV
+3.89%
116.91
ALAB
-4.09%
10.250
UMAC
+2.40%
44.34
CELH
+1.67%

FAQ

What Stock Exchange Does Rapport Therapeutics Trade On?

Rapport Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Rapport Therapeutics?

The stock symbol for Rapport Therapeutics is "RAPP."

What Is the Rapport Therapeutics Market Cap?

As of today, Rapport Therapeutics market cap is 554.76M.

What Is Rapport Therapeutics's Earnings Per Share (TTM)?

The Rapport Therapeutics EPS (TTM) is -2.74.

When Is the Next Rapport Therapeutics Earnings Date?

Rapport Therapeutics will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is RAPP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Rapport Therapeutics Stock Split?

Rapport Therapeutics has split 0 times.

How Many Employees Does Rapport Therapeutics Have?

Rapport Therapeutics has 69 employees.

What is the current trading status of Rapport Therapeutics (RAPP)?

As of 23 Jul 2025, Rapport Therapeutics (RAPP) is trading at a price of 15.20, with a previous close of 15.20. The stock has fluctuated within a day range of 14.10 to 15.22, while its 52-week range spans from 6.43 to 29.74.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.